• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MAIA Biotechnology Inc.

    5/19/26 6:15:02 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MAIA alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Material under §240.14a-12

     

    MAIA Biotechnology, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     
     

     

    MAIA Biotechnology, Inc.

    Amendment and Supplement to the Proxy Statement

    For the Annual Meeting of Stockholders

    To be Held on May 21, 2026

     

    EXPLANATORY NOTE

     

    On April 7, 2026, MAIA Biotechnology, Inc. (“MAIA” or the “Company”) filed its definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”) for its annual meeting of shareholders to be held on June 9, 2025 (the “Annual Meeting”).

     

    The Company is amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy Statement (the “Amendment and Supplement”) to update the disclosure related to compensation received in the years ended December 31, 2025 and 2024 by the brother of the Company’s Chief Executive Officer in the section entitled “CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS” in the Proxy Statement

     

    Any proxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting.

     

    THIS AMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

     

    This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references in the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set forth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the Proxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.

     

    Amendments and Supplemental Disclosure

     

    Proxy Statement

     

    The section entitled “CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS” in the Proxy Statement is amended to include the disclosure below related compensation received by the brother of the Chief Executive Officer in the years ended December 31, 2025 and 2024 as follows:

     

    “We paid Radu Vitoc, brother of our Chief Executive Officer Vlad Vitoc total compensation of $286,321 in the year ended December 31, 2025, consisting of $213,000 in cash and 39,000 options with a value of $73,321. In the year ended December 31, 2024, we paid Radu Vitoc total compensation of $242,102, consisting of $172,500 in cash and 50,000 options with a value of $69,602. Mr. Vitoc’s compensation in each of 2025 and 2024 was in line with industry standards.”

     

    May 19, 2026

     

    -2-

     

    Get the next $MAIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAIA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MAIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

    90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy

    7/8/26 9:45:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

    Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers. THIO-101 Part C patients, who are re

    6/25/26 8:08:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

    Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University ("Winship"), is activated and now enrolling patients. The trial studies MAIA's lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell

    6/18/26 8:30:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MAIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:02:16 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:01:25 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:00:31 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MAIA
    SEC Filings

    View All

    SEC Form 8-K filed by MAIA Biotechnology Inc.

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    5/22/26 6:03:29 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by MAIA Biotechnology Inc.

    DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

    5/19/26 6:15:02 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by MAIA Biotechnology Inc.

    SCHEDULE 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

    5/15/26 11:06:21 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MAIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Chaouki Steven M

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/26 4:15:26 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Guerrero Ramiro

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/26 4:14:09 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Louie Ngar Yee

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/26 4:13:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MAIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

    SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 6:16:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:12:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:10:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MAIA
    Leadership Updates

    Live Leadership Updates

    View All

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

    Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

    3/25/25 8:46:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

    Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

    3/21/24 3:00:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care